Blog | HemaCare

HemaCare Publication Shines the Spotlight on Dedicated Donors

Apr 15, 2021 10:07:00 AM / by Nancy Andon, MSc posted in Cell Therapy, Cell Therapy Manufacturing, Immunotherapy (Immunology)

0 Comments

HemaCare scientists have just published a white paper on a new raw material sourcing paradigm that they hope will transform the industry.

The publication centers on dedicated donors; recallable donors who are reserved to specific research programs. The basic premise is that clients will be able to reserve self-identified recallable donors who possess physiological or demographic traits deemed beneficial to a particular research program.

Read More

HemaCare’s Super Donors to the Rescue!

Mar 17, 2021 10:25:00 AM / by Nancy Andon, MSc posted in Gene Therapy, Cell Therapy Manufacturing, GMP Cellular Therapeutics

0 Comments

New webinar highlights the benefits of “dedicated donor pools” - the latest offering from HemaCare to accelerate successful cell therapy research and commercialization

HemaCare, through Charles River Labs, recently hosted an educational webinar focused on their latest cell and gene therapy-related service.

HemaCare will now be working with clients to establish “dedicated donor” pools. The purpose of this new program is to establish and maintain a pool of reliable, recallable donors with client-determined physiological and/or demographic characteristics that match specific client research projects and programs.

Read More

HemaCare Publication Shines Spotlight on Healthy Donors

Dec 10, 2019 10:02:00 AM / by Nancy Andon, MSc posted in Cell Therapy, Cell Therapy Manufacturing

0 Comments

HemaCare is pleased to announce the publication of their latest article [1] in the current issue of BioProcess International.

The piece, entitled “The Cell Therapy Industry Needs High-Quality Healthy-Donor Material”, gives readers expert insight into the growing demand for cell therapy starting material, and how that demand is impacting suppliers.

Read More

HemaCare Starting Material Provides Real-Time Data on Therapeutic Cell Quality

Jun 18, 2019 10:04:00 AM / by Nancy Andon, MSc posted in Cell Therapy, Cell Therapy Manufacturing

0 Comments

Scientists at the Cell and Gene Therapy Catapult in the U.K. cite using HemaCare leukopaks to study a new method of scrutinizing cellular quality markers during cell therapy bioprocessing. [1]

The publication represents a collaborative effort among scientists developing cellular therapies in the United States and Canada as well as in the U.K. They are working together to solve a key issue; how to ensure the consistent high quality of their living products.

Read More

Positioning Cell Therapies for Success -Part 2: Supply Chain Requirements

Jun 11, 2019 10:05:00 AM / by Nancy Andon, MSc posted in Cell Therapy, Cell Therapy Manufacturing, GMP Cellular Therapeutics

0 Comments

Last week in Part 1 of our series, we presented observations from industry leaders into how they plan for success by installing comprehensive quality management systems and laying down detailed groundwork for an optimized transition to GMP-compliant starting materials and technologies. This week in Part 2 of our series, cell therapy manufacturers present their own perceptions of what constitutes an ideal cell therapy starting material supplier, as well as what can be done on their end to ensure their cell therapy retains consistent quality and potency. 

Read More

      Subscribe Here!

      Posts by Topic

      see all

      Recent Posts